Dosing & Uses
Gastric Adenocarcinoma
Pending FDA approval for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are Claudin 18.2 (CLDN18.2)-positive
Next:
Pharmacology
Mechanism of Action
First-in-class investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody
Claudins are present throughout the body and are a major component of tight junctions, which are involved in controlling the flow of molecules between cells
CLDN18.2 is the dominant isoform in normal gastric tissue and is often retained in malignant transformation
Previous
Next:
Images
No images available for this drug.
Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
